RxDoctor Payments Data

Terri Roberts

Family · Winnfield, LANPI 1518243526

Payments from drug & device makers

$470in general payments, 2019–2025

Across 27 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$93
  • Axsome Therapeutics, Inc.$66
  • Supernus Pharmaceuticals, Inc.$49
  • Insulet Corporation$37
  • Novo Nordisk$31
  • Pfizer$30
  • plus $164 from 10 others

What the payments were for

  • Food & beverage$470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$470 in reported general payments places this provider in the 45th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,972
Medicare patients
78
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide162$164,436
MounjaroTirzepatide71$87,553
TrulicityDulaglutide52$87,550
JardianceEmpagliflozin82$83,691
EliquisApixaban47$57,993
RybelsusSemaglutide23$38,130
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,159
Repatha SureclickEvolocumab30$16,611
VraylarCariprazine Hcl11$15,339
XareltoRivaroxaban13$13,581
FarxigaDapagliflozin Propanediol15$13,262
BelsomraSuvorexant29$12,338
LinzessLinaclotide15$11,244
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$7,131
ConcertaMethylphenidate Hcl12$4,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$31$203,659196 claims
Lilly USA, LLCMounjaro, Trulicity$12$175,103123 claims
PfizerEliquis$30$57,99347 claims
GSKTrelegy Ellipta$15$29,15931 claims
AbbVieVraylar, Linzess$93$26,58326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,610 family providers in Louisiana.

Other family in Winnfield

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →